Dermata Therapeutics, Inc. (DRMA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.76
- As of
Kresmion compiles this page from DRMA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Dermata Therapeutics, Inc. (DRMA): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-29.
See the full DRMA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for DRMA on one page. Preview it with sample data, then open it live with a free account.
Preview the DRMA dossierActive events for DRMA
- mediumEarnings below estimates
Q2-2026: Missed consensus by 31.9%, EPS $-0.74 vs $-0.561 estimate
- mediumEarnings above estimates
Q2-2025: Beat consensus by 43.9% - EPS $-1.66 vs $-2.958 estimate
- mediumEarnings above estimates
Beat consensus by 43.9% - EPS $-1.66 vs $-2.958 estimate
- mediumEarnings above estimates
Q1-2026: Beat consensus by 11.2% - EPS $-0.48 vs $-0.5406 estimate
FREE, NO ACCOUNT
Every event on DRMA, as it fires
New filings, 13F moves and cross asset events on DRMA land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter.
Recent SEC filings, DRMA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
Going concern statement
DRMA's 10-Q filed Aug 11, 2026 states:
These factors raise substantial doubt about the Company's ability to continue as a going concern for the one-year period following the date that these financial statements were issued.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on DRMA
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in DRMA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on DRMA in the last 180 days.
Upstream: SEC EDGAR filings for DRMA
Kresmion, "Dermata Therapeutics, Inc. (DRMA) institutional holdings and SEC filings", data as of 2026-10-29, https://kresmion.com/research/DRMA. Upstream data: SEC EDGAR filings for DRMA.
Link to this data (HTML):
<a href="https://kresmion.com/research/DRMA">Dermata Therapeutics, Inc. (DRMA) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow DRMA on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to DRMA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.